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Aliskiren and losartan  
in patients with type 2 diabetes  
and nephropathy
Among patients with type 2 diabetes mellitus, angiotensin 
receptor blockers have improved renal outcomes. In an 
attempt to further suppress proteinuria and improve outcomes, 
angio tensin-converting enzyme inhibitors (ACEIs) have been 
used in combination with angiotensin receptor blockers 
(ARBs). Combination ACEI/ARB therapy has inconsistently 
resulted in better outcomes but has more consistently resulted 
in higher rates of adverse events.
In a new study by Parving et al., patients were randomized 
to receive the ARB losartan or losartan plus the ACEI aliskiren 
for 24 weeks. The primary outcome was a reduction in the ratio 
of urinary albumin to creatinine measured at 6 months. Treat-
ment with aliskiren reduced the urinary albumin-to-creatinine 
ratio by 20% as compared with placebo (P < 0.001). At week 
24, the overnight urinary albumin excretion rate showed a 
similar reduction of 18% in the aliskiren group (P = 0.009). 
Patients receiving placebo did not demonstrate a change in 
albumin-to-creatinine ratio, urinary albumin excretion rate, 
or blood pressure over 6 months. The albumin-to-creatinine 
ratio and urinary albumin excretion rates lowered significantly 
in patients receiving aliskiren, while blood pressure was similar 
to that in the placebo group and remained the same. All sub-
groups had similar reduction in albuminuria, based on gender 
or race, age, the presence of albuminuria, glomerular filtra-
tion rate, systolic and diastolic blood pressure, and glycated 
hemoglobin. Most notably, the group receiving aliskiren did 
not have an increased risk of either adverse events or serious 
adverse events.
Given that the benefits of aliskiren were independent of 
the urinary albumin excretion rate, the combination therapy 
could be used in all patients in whom suppression of micro-
albuminuria is the goal. A second option is to add aliskiren 
to an ARB after the failure of the ARB to achieve the targeted 
albumin excretion rate. The cost of drugs as well as the benefit 
of lowering albumin excretion rates among patients in whom 
microalbuminuria is already well suppressed will need to be 
defined when choosing between these two treatment strategies. 
(N Engl J Med 2008; 358: 2433–2446)
Lynda Szczech
The proteasome inhibitor 
bortezomib protects mice with 
lupus-like disease from nephritis
Antibody-mediated diseases such as systemic lupus 
erythematosus (SLE) are frequently difficult to treat and often 
do not achieve remission despite aggressive therapies such as 
high-dose glucosteroids and cyclophosphamide. Autoanti-
bodies against multiple targets are critically involved in the 
pathogenesis of antibody-mediated diseases, and treatments 
are designed to decrease autoantibody generation. Current 
therapies can efficiently attack B lymphocytes, plasmablasts, 
and short-lived plasma cells but not long-lived plasma cells, 
which are resistant even to autologous and allogeneic stem-cell 
transplantations. The ubiquitin–proteasome pathway regulates 
intracellular protein turnover, and its function is crucial to 
cellular homeostasis. Proteasome inhibitors were initially syn-
thesized as probes of proteolytic processes but were soon used 
as anticancer drugs when they were found to induce apoptosis 
preferentially in transformed cells.
The sensitivity of myeloma cells toward proteasome 
inhibitors was recently found to directly correlate with their 
immuno globulin synthesis rates. Hence, Neubert et al. hypo-
thesized that normal plasma cells may also be hypersensitive to 
proteasome inhibition owing to their extremely high amount of 
protein biosynthesis. NZB/W F1 mice spon taneously develop a 
disease closely resembling human SLE, and cyclophosphamide-
resistant long-lived plasma cells represent a large fraction of 
autoreactive antibody-producing cells in the spleen. Using 
these mice, the authors found that the proteasome inhibitor 
bortezomib, which is approved for the treatment of multiple 
myeloma, eliminated both short- and long-lived plasma cells. 
Treatment with bortezomib depleted plasma cells producing 
antibodies against double-stranded DNA eliminated auto-
antibody production, and ameliorated glomerulonephritis 
(Figure). The drug prolonged survival of NZB/W F1 mice and 
another mouse strain with lupus-like disease, MRL/lpr mice. 
The elimination of plasma cells producing pathogenic autoanti-
bodies represents a key therapeutic goal for efficient treatment 
of antibody-mediated diseases. Hence, the elimination of auto-
reactive plasma cells by proteasome inhibitors might represent 
a new treatment strategy for antibody-mediated diseases. (Nat 
Med 2008; 14: 748–755; doi:10.1038/nm1763)
Juan Oliver
Representative kidney sections, stained with periodic acid-Schiff stain 
(top) or anti-mouse IgG (bottom), from 60-week-old mice that had been 
treated with bortezomib (Bz) beginning at 18 weeks (middle) and 24 
weeks (right) of age and from a 40-week-old control mouse (left).
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Using whole-organ genomic 
mapping to understand the 
development of bladder cancer
The search for the genomic sequences involved in human cancers 
can be greatly facilitated by maps of genomic imbalances identify-
ing the involved chromosomal regions, particularly those that par-
ticipate in the development of occult preneoplastic conditions that 
progress to clinically aggressive invasive cancer. The integration of 
such regions with human genome sequence variation may provide 
valuable clues about their overall structure and gene content. By 
extension, such knowledge may help us understand the under-
lying genetic components involved in the initiation and progres-
sion of these cancers. Majewski et al. describe the development of 
a genome-wide map of human bladder cancer that tracks its pro-
gression from in situ precursor conditions to invasive disease. They 
performed testing for allelic losses using a genome-wide panel of 
787 microsatellite markers on multiple DNA samples extracted 
from the entire mucosal surface of the bladder and corresponding 
to normal urothelium, in situ preneoplastic lesions, and invasive 
carcinoma. The authors matched the clonal allelic losses in distinct 
chromosomal regions to specific phases of bladder neoplasia and 
produced a detailed genetic map of bladder cancer development. 
These analyses revealed three major waves of genetic changes asso-
ciated with growth advantages of successive clones and reflecting 
a stepwise conversion of normal urothelial cells into cancer cells. 
The genetic changes map to six regions at 3q22–q24, 5q22–q31, 
9q21–q22, 10q26, 13q14, and 17p13 (Figure), which may represent 
critical hits driving the development of bladder cancer. Finally, the 
authors defined a minimal deleted region associated with clonal 
expansion of in situ neoplasia. These findings provide new insights 
into the involvement of several non-coding sequences mapping 
to the region and identify novel target genes, termed ‘forerunner 
genes’, involved in early phases of cancer development. (Lab Invest 
2008; 88: 694–721; doi:10.1038/labinvest.2008.27)
Marc De Broe
Vasopressin regulates the renin–
angiotensin–aldosterone system
In addition to water metabolism, arginine vasopressin (AVP) is 
involved in multiple other functions, which are mediated by three 
AVP receptors: V1a, V1b, and V2. The V1a receptor (V1aR) is 
widely expressed (particularly in the vasculature), whereas V1bR 
and V2R are mainly expressed in the anterior pituitary gland and 
the kidney, respectively. V1aR mediates vascular contraction, cellu-
lar proliferation, platelet aggregation, glycogenolysis, lipid metabo-
lism, and glucose tolerance. In the kidney, V2R is expressed in 
the thick ascending limbs of Henle’s loop and the collecting ducts. 
Because in the kidney V1aR is also detected in the juxtaglomerular 
apparatus, thick ascending limbs, and collecting ducts, both V1aR 
and V2R are likely involved in renal excretory function. When 
Aoyagi et al. recently generated V1aR-deficient (V1aR–/–) mice, 
they found that these animals had lower circulating blood volume 
and blood pressure. Interestingly, these mice had decreased levels of 
plasma atrial natriuretic peptide and aldosterone. In a new follow-
up study, the same authors used the V1aR–/– mice to investigate 
the role of V1aR in urine concentration, renal function, and the 
renin–angiotensin system. They found that, when compared with 
wild-type controls, V1aR–/– mice had lower glomerular filtration 
rate and urinary NaCl excretion as well as renal AVP-dependent 
cAMP generation and expression of V2R and aquaporin 2. In 
addition, urine volumes of V1aR–/– mice were greater than those 
of wild-type mice, particularly during water loading, indicating 
impaired urinary-concentration ability. It is of great interest that 
plasma renin activity, angiotensin II level, and renin expression in 
the kidney were all decreased in these animals (Figure). Strikingly, 
the expression of renin stimulators such as neuronal nitric oxide 
synthase and cyclooxygenase-2 in macula densa cells, where V1aR 
was specifically expressed, was decreased in V1aR–/– mice. These 
results indicate that, in addition to its well-known effects, AVP 
regulates body fluid homeostasis and renal function via its V1a 
receptor, particularly in the macula densa cells where it activates 
the renin–angiotensin system. (Am J Physiol Renal Physiol 2008; 
295: F100–F107; doi:10.1152/ajprenal.00088.2008)
Juan Oliver
Identification of six critical chromosomal regions involved in the 
development of bladder cancer.
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Immunostaining for renin in the granular cells and renal tubule of wild-
type (WT) and V1aR–/– mouse kidneys.
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